About Us Services Careers FAQ Contact Us 0
Home Pharmaceuticals Dementia Drugs Market Size to Grow at a CAGR of 7.95% by 2030
Dementia Drugs Market

Dementia Drugs Market Size, Share & Trends Analysis Report By Indications (Lewy Body Dementia, Parkinsons Disease Dementia, Alzheimers Disease, Vascular Dementia, Other Indications), By Drug Class (MAO-B Inhibitors, Glutamate Inhibitors, Cholinesterase Inhibitors) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Report Code: SRPH3368DR
Last Updated : December 01, 2022
Author : Straits Research
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Dementia Drugs Market Introduction
    2. By Indications
      1. Introduction
        1. Indications By Value
      2. Lewy Body Dementia
        1. By Value
      3. Parkinsons Disease Dementia
        1. By Value
      4. Alzheimers Disease
        1. By Value
      5. Vascular Dementia
        1. By Value
      6. Other Indications
        1. By Value
    3. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. MAO-B Inhibitors
        1. By Value
      3. Glutamate Inhibitors
        1. By Value
      4. Cholinesterase Inhibitors
        1. By Value
    1. Introduction
    2. By Indications
      1. Introduction
        1. Indications By Value
      2. Lewy Body Dementia
        1. By Value
      3. Parkinsons Disease Dementia
        1. By Value
      4. Alzheimers Disease
        1. By Value
      5. Vascular Dementia
        1. By Value
      6. Other Indications
        1. By Value
    3. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. MAO-B Inhibitors
        1. By Value
      3. Glutamate Inhibitors
        1. By Value
      4. Cholinesterase Inhibitors
        1. By Value
    4. U.S.
      1. By Indications
        1. Introduction
          1. Indications By Value
        2. Lewy Body Dementia
          1. By Value
        3. Parkinsons Disease Dementia
          1. By Value
        4. Alzheimers Disease
          1. By Value
        5. Vascular Dementia
          1. By Value
        6. Other Indications
          1. By Value
      2. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. MAO-B Inhibitors
          1. By Value
        3. Glutamate Inhibitors
          1. By Value
        4. Cholinesterase Inhibitors
          1. By Value
    5. Canada
    1. Introduction
    2. By Indications
      1. Introduction
        1. Indications By Value
      2. Lewy Body Dementia
        1. By Value
      3. Parkinsons Disease Dementia
        1. By Value
      4. Alzheimers Disease
        1. By Value
      5. Vascular Dementia
        1. By Value
      6. Other Indications
        1. By Value
    3. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. MAO-B Inhibitors
        1. By Value
      3. Glutamate Inhibitors
        1. By Value
      4. Cholinesterase Inhibitors
        1. By Value
    4. U.K.
      1. By Indications
        1. Introduction
          1. Indications By Value
        2. Lewy Body Dementia
          1. By Value
        3. Parkinsons Disease Dementia
          1. By Value
        4. Alzheimers Disease
          1. By Value
        5. Vascular Dementia
          1. By Value
        6. Other Indications
          1. By Value
      2. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. MAO-B Inhibitors
          1. By Value
        3. Glutamate Inhibitors
          1. By Value
        4. Cholinesterase Inhibitors
          1. By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest of Europe
    1. Introduction
    2. By Indications
      1. Introduction
        1. Indications By Value
      2. Lewy Body Dementia
        1. By Value
      3. Parkinsons Disease Dementia
        1. By Value
      4. Alzheimers Disease
        1. By Value
      5. Vascular Dementia
        1. By Value
      6. Other Indications
        1. By Value
    3. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. MAO-B Inhibitors
        1. By Value
      3. Glutamate Inhibitors
        1. By Value
      4. Cholinesterase Inhibitors
        1. By Value
    4. China
      1. By Indications
        1. Introduction
          1. Indications By Value
        2. Lewy Body Dementia
          1. By Value
        3. Parkinsons Disease Dementia
          1. By Value
        4. Alzheimers Disease
          1. By Value
        5. Vascular Dementia
          1. By Value
        6. Other Indications
          1. By Value
      2. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. MAO-B Inhibitors
          1. By Value
        3. Glutamate Inhibitors
          1. By Value
        4. Cholinesterase Inhibitors
          1. By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Taiwan
    10. South East Asia
    11. Rest of Asia-Pacific
    1. Introduction
    2. By Indications
      1. Introduction
        1. Indications By Value
      2. Lewy Body Dementia
        1. By Value
      3. Parkinsons Disease Dementia
        1. By Value
      4. Alzheimers Disease
        1. By Value
      5. Vascular Dementia
        1. By Value
      6. Other Indications
        1. By Value
    3. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. MAO-B Inhibitors
        1. By Value
      3. Glutamate Inhibitors
        1. By Value
      4. Cholinesterase Inhibitors
        1. By Value
    4. UAE
      1. By Indications
        1. Introduction
          1. Indications By Value
        2. Lewy Body Dementia
          1. By Value
        3. Parkinsons Disease Dementia
          1. By Value
        4. Alzheimers Disease
          1. By Value
        5. Vascular Dementia
          1. By Value
        6. Other Indications
          1. By Value
      2. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. MAO-B Inhibitors
          1. By Value
        3. Glutamate Inhibitors
          1. By Value
        4. Cholinesterase Inhibitors
          1. By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest of MEA
    1. Introduction
    2. By Indications
      1. Introduction
        1. Indications By Value
      2. Lewy Body Dementia
        1. By Value
      3. Parkinsons Disease Dementia
        1. By Value
      4. Alzheimers Disease
        1. By Value
      5. Vascular Dementia
        1. By Value
      6. Other Indications
        1. By Value
    3. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. MAO-B Inhibitors
        1. By Value
      3. Glutamate Inhibitors
        1. By Value
      4. Cholinesterase Inhibitors
        1. By Value
    4. Brazil
      1. By Indications
        1. Introduction
          1. Indications By Value
        2. Lewy Body Dementia
          1. By Value
        3. Parkinsons Disease Dementia
          1. By Value
        4. Alzheimers Disease
          1. By Value
        5. Vascular Dementia
          1. By Value
        6. Other Indications
          1. By Value
      2. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. MAO-B Inhibitors
          1. By Value
        3. Glutamate Inhibitors
          1. By Value
        4. Cholinesterase Inhibitors
          1. By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest of LATAM
    1. Dementia Drugs Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Apotex Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. AstraZeneca
    3. Aurobindo Pharma
    4. Eisai Co. Ltd
    5. Eli Lilly and Company
    6. Johnson & Johnson
    7. Pfizer Inc.
    8. Teva Pharmaceuticals
    9. Zydus Pharmaceuticals
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The global dermatological drugs market size was valued at USD 17.09 billion in 2021, and it is anticipated to reach USD 37.85 billion by 2030 at a CAGR of 10.45% during the forecast period(2022-2030). The primary focus of the medical speciality known
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.